<DOC>
	<DOCNO>NCT00576108</DOCNO>
	<brief_summary>This study evaluate safety efficacy 2 week topical KD7040 versus placebo treatment postherpetic neuralgia .</brief_summary>
	<brief_title>A 2 Week Study Topical KD7040 Treatment Postherpetic Neuralgia ( PHN )</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<criteria>Male female subject age 1885 year Previous diagnosis Shingles ( Herpes Zoster ) pain persist least 3 month , long 5 year , heal rash Subject intact skin target treatment area Female subject childbearing potential must negative serum pregnancy test screening , negative urine human chorionic gonadotropin ( hCG ) test prior randomization , must use medically acceptable method birth control . All subject must agree take every precaution ensure pregnancy occur study . Subject must willing able complete screen study procedure describe int protocol . Subject must voluntarily provide write Informed Consent prior participation . Subjects know hypersensitivity KD7040 methylparaben , previous exposure KD7040 . Subjects pregnant , nurse plan become pregnant . Subjects immunocompromised clinically significant hematological abnormality . Subjects system dermatological condition ( e.g. , psoriasis , atopic dermatitis ) impair wound heal . Subjects local anesthetic nerve block within 48 hour study entry . Subjects sever pain may confound assessment PHN . Subjects serious , unstable , clinically significant medical psychological condition , , opinion Investigator ( ) would compromise subject ' participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>